Connect your AI

Bausch Health Companies BHC Restricted Cash

Restricted Cash at other companies

Bausch + LombBLCO

$11M-15.4%

ANI PharmaceuticalsANIP

$36K+5.9%

TG TherapeuticsTGTX

$1.35M+3.8%

Ocular TherapeutixOCUL

$1.61M0.0%

Neurocrine BiosciencesNBIX

——

ViatrisVTRS

——

Other financials

Income statement

Revenue$2.5B+11.7%

Operating income-$950.0M-444%

Net income-$1.4B-2,353%

EPS (diluted)-$3.82-2,287%

Balance sheet

Cash & equivalents$1.3B+13.4%

Total debt$20.8B-3.5%

Total equity-$2.1B-74.0%

Total assets$24.5B-7.3%

Cash flow

Operating cash flow$230.0M+9.0%

CapEx$109.0M-5.2%

Free cash flow$121.0M+26.0%

Valuation

Market cap$1.86B-15.9%

Profitability

Gross margin71.4%—

Operating margin5.6%-10.3pp

Net margin-1.9%-0.9pp

FCF margin9.8%-2.8pp

Returns & leverage

Return on equity-70.1%—

Debt / equity45.2×—

Current ratio1.3×0.0×

Where this comes from

Reported directly by Bausch Health Companies in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.

The official record: Bausch Health Companies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bausch Health Companies's restricted cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Bausch Health Companies's restricted cash?: Bausch Health Companies (BHC) reported restricted cash of $13M in Q1 2026.
How has Bausch Health Companies's restricted cash changed year-over-year?: Bausch Health Companies's restricted cash decreased by 43.5% year-over-year, from $23M to $13M.
What is the long-term trend for Bausch Health Companies's restricted cash?: Over 4 years (2020 to 2025), Bausch Health Companies's restricted cash has grown at a -66.1% compound annual growth rate (CAGR), from $1.21B to $16M.
What does restricted cash mean?: Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.